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Crystallopathies are a heterogeneous group of diseases caused by intrinsic or environ-
mental microparticles or crystals, promoting tissue inflammation and scarring. Certain 
proteins interfere with crystal formation and growth, e.g., with intrarenal calcium oxalate 
(CaOx) crystal formation, a common cause of kidney stone disease or nephrocalcinosis- 
related chronic kidney disease (CKD). We hypothesized that immunoglobulins can 
modulate CaOx microcrystal formation and crystal growth and that therefore, biologi-
cal IgG-based drugs designed to specifically target disease modifying proteins would 
elicit a dual effect on the outcome of CaOx-related crystallopathies. Indeed, both the 
anti-transforming growth factor (TGF)β IgG and control IgG1 antibody impaired CaOx 
crystallization in vitro, and decreased intrarenal CaOx crystal deposition and subsequent 
CKD in mice on an oxalate-rich diet compared to oxalate-fed control mice. However, the 
TGFβ-specific IgG antibody showed nephroprotective effects beyond those of control 
IgG1 and substantially reduced interstitial fibrosis as indicated by magnetic resonance 
imaging, silver and α-smooth muscle actin staining, RT-qPCR, and flow cytometry for 
pro-fibrotic macrophages. Suppressing interstitial fibrosis slowed the decline of glomer-
ular filtration rate (GFR) compared to treatment with control IgG1 [slope of m = −8.9 
vs. m = −14.5 μl/min/100 g body weight (BW)/day, Δ = 38.3%], an increased GFR at 
the end of the study (120.4 vs. 42.6 μl/min/100 g BW, Δ = 64.6%), and prolonged end 
stage renal disease (ESRD)-free renal survival by 10 days (Δ = 38.5%). Delayed onset 
of anti-TGFβ IgG from day 7 was no longer effective. Our results suggest that biological 
drugs can elicit dual therapeutic effects on intrinsic crystallopathies, such as anti-TGFβ 
IgG antibody treatment inhibits CaOx crystallization as well as interstitial fibrosis in 
nephrocalcinosis-related CKD.
Keywords: calcium oxalate, crystallization, transforming growth factor β, fibrosis, nephrocalcinosis, chronic 
kidney disease
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inTrODUcTiOn
Crystal deposition is relatively common in the kidneys and is 
often associated with inflammation, tubular injury, and intersti-
tial fibrosis (1). Crystals of calcium oxalate (CaOx) are commonly 
found in kidney stone disease (1) accounting for approximately 
80% of all types of kidney stones and can cause chronic kidney 
disease (CKD) (2). Unlike symptomatic urolithiasis, intrarenal 
nephrocalcinosis is often asymptomatic, but can lead to significant 
kidney injury and renal failure (3–5). The mechanism of CaOx 
crystal formation involves a combination of processes including 
urine supersaturation of stone-forming salts, such as calcium and 
oxalate, urinary pH, and lack of crystallization inhibitors in the 
urine (6, 7). These crystallization inhibitors like nephrocalcin, 
osteopontin (8), Tamm–Horsfall glycoprotein (9), and uropontin 
(10) have been identified in the urine of healthy individuals but 
they are decreased in kidney stone formers. Interactions between 
CaOx crystals and the tubular compartment evoking an inflam-
matory response associated with the release of pro-inflammatory 
mediators, cell death, and leukocyte infiltration, which further 
contributes to tubular atrophy and interstitial fibrosis, leading 
to progressive nephrocalcinosis (11). We first speculated that 
proteins potentially suitable for therapy in humans could have a 
similar protective effect on CaOx crystallization, e.g., immuno-
globulin (IgG).
Therapies to prevent renal failure from CaOx crystal-induced 
nephropathy and/or nephrocalcinosis have been directed prin-
cipally at lowering serum and urine oxalate, the use of an 
oxalate-reduced diet and calcium supplementation in patients 
with enteric hyperoxaluria, as well as anti-inflammatory therapies 
(12). CKD progression in nephrocalcinosis is associated with 
profound interstitial fibrosis (13), a histopathological feature of 
kidney atrophy thought to contribute to CKD progression (14). 
Transforming growth factor (TGF)β is a critical mediator of 
organ fibrosis and has been repeatedly validated as a molecular 
target in disease (15). However, in renal fibrosis only few studies 
assessed glomerular filtration rate (GFR), a clinically relevant 
marker of renal excretory function, as an endpoint in studies with 
interventions modeling renal fibrogenesis.
We hypothesized that anti-TGFβ IgG may not only inhibit 
interstitial fibrosis but also influence the crystallization of CaOx 
inside the kidney, which both should synergize to prevent 
nephrocalcinosis-related GFR decline, i.e., CKD progression. To 
address this concept, we employed a mouse model of progressive 
CaOx crystal-driven CKD (13) with preemptive or delayed anti-
TGFβ IgG treatment (16, 17).
MaTerials anD MeThODs
animal studies
Eight-week old male C57BL/6N mice were obtained from Charles 
River Laboratories (Sulzfeld, Germany). Mice were housed in 
groups of five in filter-top cages and had access to food and water 
ad  libitum. Cages, nest lets, food, and water were sterilized by 
autoclaving before use. Oxalate-rich diet was prepared by adding 
50 µmol/g sodium oxalate to a calcium-free standard diet (Ssniff, 
Soest, Germany) as previously described (13, 18). Mice were split 
into four groups (n = 5 mice per group): the first group received 
a control diet without sodium oxalate (control), the second group 
was injected intraperitoneally (i.p.) with the murine control IgG1 
monoclonal antibody (isotype-matched control 13C4 antibody), 
the third group with the murine IgG1 monoclonal anti-TGFβ 
antibody that neutralizes all three TGFβ isoforms (1D11, both 
antibodies kindly provided by Genzyme Corporation, Sanofi, 
Framingham, MA, USA) 1 day after starting the oxalate-rich diet 
every alternate day [1.5 mg/kg body weight (BW), total of seven 
injections] (16, 19), and the fourth group received an oxalate-rich 
diet only (oxalate only). Serum and urine samples were collected 
as well as GFR measured from all experimental and control 
groups on day 0 and before sacrifice by cervical dislocation on 
day 7 or 14. Urine samples were acidified immediately after col-
lection for oxalic acid estimations. Kidneys were harvested after 
sacrifice. One kidney was used for flow cytometry analysis and 
the other was divided into two equal parts. One part was kept in 
RNA later solution at −80°C for RNA isolation and the second 
part was kept in 4% formalin to be embedded in paraffin for 
histology analysis.
For delayed IgG1 or anti-TGFβ antibody treatment, all mice 
were put on a control diet (n = 5) or an oxalate-rich diet (n = 5) 
and two groups of mice received additionally either the control 
IgG1 antibody (i.p., 1.5  mg/kg BW, n =  5) or the anti-TGFβ 
antibody (i.p., 1.5  mg/kg BW, n =  5) four times starting from 
day 7 every alternate day until sacrifice on day 14 (Figure S1 in 
Supplementary Material).
assessment of Kidney injury
Kidney sections of 2 µm were stained with Pizzolato to visualize 
CaOx crystal deposition, which was quantified (% area) using 
ImageJ software as described previously (20). Periodic acid-Schiff 
(PAS) reagent was used to assess kidney injury, which was scored 
by assessing the percentage of atrophic tubules. CD3+ T cells and 
F4/80+ macrophages (both Serotec, Kidlington, UK) were identi-
fied by immunostaining. Fibrotic areas were identified by immu-
nostaining for silver and α-smooth muscle actin (α-SMA) (Dako 
GmbH, Hamburg, Germany). Quantification of immunostaining 
(% area) was done using ImageJ software. An observer blinded 
to the experimental condition performed all assessments. Serum 
blood urea nitrogen (BUN) (DiaSys, Holzheim, Germany), 
serum and urine oxalic acid (oxalate) (Libios, Pontcharra-sur- 
Turdine, France), and urine calcium (Sigma-Aldrich, Taufkirchen, 
Germany) were measured using commercially available kits as 
per manufacturer’s protocol.
Transcutaneous gFr assessment and 
calculation
Glomerular filtration rate measurements were performed in 
conscious mice on day 0, 7, and 14 (n =  5 per group). Briefly, 
mice were anesthetized with isoflurane to mount a miniaturized 
imager device built from two light-emitting diodes, a photodiode, 
and a battery (MediBeacon™ Inc., Mannheim, Germany) onto 
the shaved neck of the animals (21). The background signal of 
the skin was recorded for 5  min. Then, mice received a single 
injection of FITC-sinistrin (i.v., 150 mg/kg BW) (MediBeacon™ 
Table 1 | Murine primer sequences.
Target Primer sequences
KIM-1 Forward 5′-TCAGCTCGGGAATGCACAA-3′
Reverse 5′-TGGTTGCCTTCCGTGTCTCT-3′
TIMP-2 Forward 5′-CAGACGTAGTGATCAGAGCCAAA-3′
Reverse 5′-ACTCGATGTCTTTGTCAGGTCC-3′
IL-6 Forward 5′-TGATGCACTTGCAGAAAACA-3′
Reverse 5′-ACCAGAGGAAATTTTCAATAGGC-3′
TNFα Forward 5′-CCACCACGCTCTTCTGTCTAC-3′
Reverse 5′-AGGGTCTGGGCCATAGAACT-3′
ACOX1 Forward 5′-CTTGGATGGTAGTCCGGAGA-3′
Reverse 5′-TGGCTTCGAGTGAGGAAGTT-3′
PGC1α Forward 5′-AGTCCCATACACAACCGCAG-3′
Reverse 5′-CCCTTGGGGTCATTTGGTGA-3′
PPARα Forward 5′-TGCAAACTTGGACTTGAACG-3′
Reverse 5′-GATCAGCATCCCGTCTTTGT-3′
TGFβ1 Forward 5′-CAACCCAGGTCCTTCCTAAA-3′
Reverse 5′-GGAGAGCCCTGGATACCAAC-3′
TGFβR1 Forward 5′-GCTCCTCATCGTGTTGGTG-3′
Reverse 5′-CAGTGACTGAGACAAAGCAAAGA-3′
TGFβ2 Forward 5′-CCGCATCTCCTGCTAATGTTG-3′
Reverse 5′-AATAGGCGGCATCCAAAGC-3′
TGFβR2 Forward 5′-GCTGCATATCGTCCTGTGG-3′
Reverse 5′-TCACATCGCAAAACTTGCAC-3′
Collagen1α1 Forward 5′-ACATGTTCAGCTTTGTGGACC-3′
Reverse 5′-TAGGCCATTGTGTATGCAGC-3′
Fibronectin-1 Forward 5′-GGAGTGGCACTGTCAACCTC-3′
Reverse 5′-ACTGGATGGGGTGGGAAT-3′
iNOS Forward 5′-GAGACAGGGAAGTCTGAAGCAC-3′
Reverse 5′-CCAGCAGTAGTTGCTCCTCTTC-3′
18s RNA Forward 5′-GCAATTATTCCCCATGAACG-3′
Reverse 5′-AGGGCCTCACTAAACCATCC-3′
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Inc., Mannheim, Germany). Each mouse was kept in a single cage 
and the signal was recorded for 90 min. Data were analyzed using 
the imaging device MPD Studio software (MediBeacon™ Inc., 
Mannheim, Germany). GFR (μl/min/100 g BW) was calculated 
from the decrease of fluorescence intensity of FITC-sinistrin over 
time using the three-compartment model with linear correction 
(injection, plasma, and interstitial compartment, t1/2 of FITC-
sinistrin), BW of mouse, and an empirical conversion factor as 
per manufacturer’s protocol (21, 22). The slope of daily GFR loss 
(m) was determined with the linear equation using Microsoft 
Excel
 
GFR L/min/100g BW
14,616.8 [ L per 100g BW]
FITC s
µ
µ
  =
−t 1
2
( inistrin  [minute])
.
 
caOx crystal Formation In Vitro
The formation of CaOx crystals in  vitro has previously been 
described in more detail (7). Briefly, 50 µl of a Na2C2O4 solution 
(oxalate, 0.1 mM, pH 7.3) was mixed with 50 µl CaCl2 solution 
(0.1 mM, pH 7.3) in a 96-well plate at room temperature (RT) for 
5 min (CaOx only). To investigate the effect of the IgG1 or anti-
TGFβ antibody on CaOx crystal formation, Na2C2O4 solution was 
pre-incubated with or without the IgG1 or anti-TGFβ antibody 
(0.2 µg/ml) or an IgG F(ab′)2 fragment antibody (0.2 µg/ml) for 
1 h at RT prior to addition of CaCl2 buffer (CaOx + IgG1). Different 
forms of CaOx crystals [CaOx monohydrate (COM) and CaOx 
dihydrate (COD)] were visualized under a Leica microscopy 
and quantified using flow cytometry (BD FACSCalibur, Becton 
Dickinson, NJ, USA).
rna Preparation and real-Time 
Quantitative Pcr
The RNA extraction kit from Qiagen (Düsseldorf, Germany) 
was used to isolate total RNA from kidneys (n = 5 per group) 
following the manufacturer’s instructions. RNA quality was 
assessed using agarose gels before being transcribed into cDNA 
using reverse transcriptase (Superscript II) (Invitrogen, Carlsbad, 
CA, USA). Real-time RT-PCR was performed using SYBRGreen 
PCR master mix and analyzed with a Light Cycler 480 (Roche, 
Mannheim, Germany). All gene expression values were normal-
ized using 18s rRNA as a housekeeping gene. All primers used 
for amplification were purchased from Metabion (Martinsried, 
Germany) and are listed in Table 1.
Flow cytometry analysis
Kidneys were harvested from mice and then digested in diges-
tion buffer (collagenase/DNase1 solution) for 40  min at 37°C. 
Digested tissue was passed through a 70 µm filter and washed with 
cold PBS. For isolating leukocytes, a Nycodenz solution (Axis-
Shield, Oslo, Norway) was used to separate CaOx crystals and 
tissue from renal immune cells. Single cell suspensions were then 
washed with wash buffer (0.1% BSA, 0.01% sodium azide in PBS) 
and FcR blocked with anti-mouse CD16/32 (2.4G2) for 5 min. 
After blocking, cells were stained with the surface antibodies PE/
Cy5 anti-mouse CD45 (BioLegend, Fell, Germany), V450 anti-
mouse CD11b (BioLegend, Fell, Germany), APC anti-mouse 
F4/80 (BioRad, München, Germany), FITC anti-mouse CD206 
(BD Biosciences, Germany), and PE anti-mouse Cx3CR1 (BD 
Biosciences, Heidelberg, Germany) for 30  min at 4°C in the 
dark. Following incubation, cells were washed, centrifuged, 
and GolgiPlug added for 15 min to avoid release of intracellular 
cytokines. Cells were then washed, resuspended in cell fixation/
permeabilization buffer for an additional 15 min and washed in 
perm wash buffer. Intracellular antibody for PE/Cy7 anti-mouse 
TGFβ1 was added to the cell suspension for 40 min at 4°C. After 
incubation, cells were washed with PBS and reconstituted in 1 ml 
fresh wash buffer. Flow cytometry analysis was performed using 
the BD FACSCanto II (Becton Dickinson, NJ, USA) and data ana-
lyzed with the software FlowJo 8.7 (Tree Star Inc., Ashland, OR, 
USA). For determining the absolute number of cells/microlitre, 
Invitrogen AccuCheck counting beads (Thermo Fisher Scientific, 
PCB100, Langenselbold, Germany) were used and the absolute 
cell counts calculated according to manufacturer’s instruction.
Magnetic resonance imaging (Mri)
Kidneys from IgG1- and anti-TGFβ-treated mice with nephro-
calcinosis on day 14 (n =  4 each group) were harvested and 
processed in 1.5% agarose gel, and placed in a whole body coil 
for mice (Bruker BioSpin, Ettlingen, Germany) of a dedicated 
4Steiger et al. Anti-TGF-β in Nephrocalcinosis
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small animal ultra-high-field magnetic resonance tomograph 
scanner (ClinScan 7  T, Bruker BioSpin, Ettlingen, Germany). 
Standard sequences for morphology and mapping of T1 and T2 
relaxation times (Siemens, Erlangen, Germany) were performed 
on kidneys in sagittal orientation. By mapping of relaxation 
times, specific magnetic properties of tissues are quantified. An 
increase of T1 relaxation time is associated with fibrosis, while 
prolonged T2 relaxation times are found in inflammation (13). 
For post-processing of images, three regions of interest were 
placed in the cortex, outer and inner medulla, respectively, 
to determine T1 and T2 relaxation times (Osirix, Bernex, 
Switzerland, open-source software).
Microscale Thermophoresis
MST was used to characterize binding affinity between IgG1 and 
soluble sodium oxalate. Soluble oxalate at various concentrations 
(1 nM–5 mM) and IgG1 (250 nM) were incubated for 1 h at RT. 
Measurements were performed with the Monolith NT.LabelFree 
MST device using standard capillaries (NanoTemper Techno-
logies, Munich, Germany). Buffer only, soluble sodium oxalate or 
IgG1 only were used as controls. Measurements were performed 
at 25°C in 67 mM NaPO4 buffer, 150 mM NaCl, and 0.05% Tween 
20 at pH 7.4. The infrared laser power was between 20 and 40%, 
and 40–70% LED power was used. A laser on time of 30 s and a 
laser off time of 5 s were used. Data from the binding assays were 
analyzed using Nanotemper analysis.
statistical analysis
Statistical analysis was carried out using Student’s t-test, two-way 
ANOVA with Bonferroni’s correction, or one-way ANOVA with 
Tukey’s comparison and performed using GraphPad Prism5.0 
Software. Data are presented as mean ± SEM. Significance was 
considered to be attained at a value of p < 0.05, ns indicates not 
significant.
resUlTs
igg1 influences caOx crystal Formation 
Without binding to soluble Oxalate In Vitro
Calcium oxalate can crystallize in three different hydrate forms: 
COM, COD, and CaOx trihydrate crystals (7). Among these, COM 
crystals are the most common form of CaOx crystals present in 
urinary calculi in humans compared to COD crystals (23, 24). 
To investigate whether a monoclonal anti-TGFβ IgG antibody 
can directly influence CaOx crystal formation, we pre-incubated 
Na2C2O4 (sodium oxalate) with the anti-TGFβ IgG or the control 
IgG1 antibody followed by addition of CaCl2 (calcium chloride) 
to form CaOx crystals in vitro. Light microscopy revealed that 
COM crystals were predominantly formed whereas in the pres-
ence of anti-TGFβ or IgG1 the number of CaOx crystals decreased 
compared to CaOx only (Na2C2O4 +  CaCl2 only) (Figure  1A). 
Using flow cytometry analysis, we identified small and big COM 
crystals as well as COD crystals depending on their size (side scat-
ter vs. forward scatter), which in numbers significantly decreased 
upon pre-incubation with the anti-TGFβ or IgG1 antibody 
compared to CaOx crystals only (Figure 1B). Pre-incubated of 
sodium oxalate with only an IgG F(ab′)2 fragment prior to addi-
tion of calcium chloride revealed that the number of small and 
big COM crystals as well as COD crystals significantly decreased 
compared to CaOx alone (Figure 1B, white bars). However, no 
difference in the CaOx crystal formation was observed between 
pre-incubation with the anti-TGFβ or IgG1 antibody and the IgG 
F(ab′)2 fragment (Figure 1B). To rule out the possibility that IgG1 
could interfere with soluble oxalate, we used microscale thermo-
phoresis, a sensitive method that enables the quantitative analysis 
of molecular interactions in solution based on the movement of 
molecules along temperature gradients (25–27). Incubation of 
soluble oxalate with IgG1 revealed that soluble oxalate did not 
bind to IgG1 (data not shown). These findings indicate that IgG 
antibodies and even only the IgG F(ab′)2 fragment can directly 
affect CaOx crystal formation in vitro.
igg1 antibody Treatment ameliorates 
renal Outcome in chronic Oxalate 
nephropathy In Vivo
To investigate whether the effect of anti-TGFβ IgG antibody 
treatment on CaOx crystal formation also applies in  vivo, we 
used a previously characterized mouse model of CaOx crystal-
induced nephropathy (13). Feeding mice a high-oxalate diet 
resulted in the deposition of CaOx crystals in the cortex, as 
well as the outer and inner medulla compared to mice receiv-
ing the control diet, as illustrated by the % area of CaOx crystal 
deposition in Figure  2A (red bars). Early administration of 
hyperoxaluric mice with the anti-TGFβ (oxalate +  anti-TGFβ) 
or control IgG1 antibody (oxalate + IgG1) significantly reduced 
intrarenal CaOx crystal deposits compared to untreated mice 
with nephrocalcinosis (oxalate only) after 14 days (Figure 2A). 
Serum as well as urinary oxalate levels significantly increased fol-
lowing oxalate feeding, whereas antibody treatment significantly 
reduced oxaluria in mice with nephrocalcinosis (Figure S1 in 
Supplementary Material). Urinary calcium levels rather declined 
upon feeding a calcium-depleted diet without being affected 
by antibody treatment (Figure S1 in Supplementary Material). 
Water intake was 0.2 ml/g BW in the control group (n = 5 per 
cage) and 0.29 ml/g BW in the oxalate only group (n = 5 per cage) 
on day 14 (data not shown).
Preemptive anti-TGFβ and IgG1 antibody treatment improved 
renal function, as indicated by decreased serum BUN levels 
(Figure 2B) compared to animals receiving a high-oxalate diet 
only after 14 days. This data was in line with progressive tubular 
atrophy and dilation in mice with nephrocalcinosis (oxalate 
only), which significantly decreased following preemptive 
administration of the antibodies, as indicated by PAS staining 
(Figure 2C) and intrarenal mRNA expression levels of the kid-
ney injury marker-1 and tissue inhibitor of metalloproteinase-2 
(Figure  2D). We did not observe any differences in the above 
measured parameters between the oxalate only and the antibody-
treated groups on day 7 (data not shown). The data indicate 
that anti-TGFβ IgG prevents mice from CaOx crystal-induced 
nephropathy by influencing CaOx crystal formation.
FigUre 1 | IgG1 affects calcium oxalate (CaOx) crystal formation in vitro. Na2C2O4 (oxalate) solution was pre-incubated with or without the control IgG1 
(CaOx + IgG1) or anti-transforming growth factor (TGF)β IgG antibody (CaOx + anti-TGFβ) or an IgG F(ab′)2 fragment antibody [CaOx + F(ab′)2 IgG] for 1 h at room 
temperature and then CaCl2 solution added. After 5 min, CaOx monohydrate (COM) and CaOx dihydrate (COD) crystals were formed and visualized under the light 
microscope (a). Quantification of COM and COD crystals by size (forward scatter vs. sideward scatter) using flow cytometry analysis (b). Data are mean ± SEM 
(n = 5). *p < 0.05, **p < 0.01 are considered significant.
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The Dual effect of anti-TgFβ igg 
attenuates caOx crystal-related Tissue 
inflammation
Given the potential of CaOx crystals to induce tubular atrophy, 
we next looked at the effect of anti-TGFβ IgG antibody therapy on 
the inflammatory response. As shown in Figure 3A, expression 
profiling of the inflammatory mediators interleukin 6 and tumor 
necrosis factor α showed a significant increase in the mRNA lev-
els in mice with nephrocalcinosis (oxalate only) compared to the 
control group on day 14 (Figure 3A). This inflammatory response 
was significantly reduced in IgG1 antibody-treated mice and 
even further in mice treated with anti-TGFβ IgG (Figure 3A). 
FigUre 2 | Continued
6
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Nephrocalcinosis-related progressive CKD is associated with 
increasing infiltration of immune cells, e.g., macrophages into the 
renal interstitial compartment (13, 28). Using immunostaining of 
kidney sections, we observed that anti-TGFβ and IgG1 antibody 
treatment reduced the number of intrarenal CD3+ T cells and 
F4/80+ macrophages compared to mice with nephrocalcinosis 
(Figure 3B).
In a recent study, alterations in the energy metabolism includ-
ing fatty acid oxidation have been observed in kidneys from 
human subjects with CKD and in mouse models of kidney fibro-
sis (29). They also found that high levels of TGFβ during renal 
fibrosis play an important role in inhibiting fatty acid oxidation 
and thereby aggravating disease progression (29). We, therefore, 
examined the effect of anti-TGFβ treatment on the fatty acid 
metabolism. Intrarenal mRNA expression profiling revealed that 
peroxisome proliferator-activated receptor gamma coactivator 
1 alpha, peroxisome proliferator-activated receptor alpha, and 
peroxisomal acyl-coenzyme A oxidase 1 were reduced in mice 
with nephrocalcinosis (oxalate only, red bars) (Figure  3C). 
Interestingly, anti-TGFβ treatment restored the renal energy 
metabolism compared to the oxalate only group (Figure 3C). We 
confirmed that neutralizing TGFβ in vivo inhibited TGFβ signal-
ing as indicated by decreased intrarenal mRNA expression of 
TGFβ1 and TGFβ2 as well as the receptors TGFβR1 and TGFβR2 
(Figure 3D). Together, the data indicate that anti-TGFβ IgG treat-
ment prevents mice from CaOx crystal-induced inflammation 
but increased fatty acid oxidation.
The Dual effect of anti-TgFβ igg reduces 
the number of Pro-inflammatory 
Macrophages
Different macrophage phenotypes are associated with either 
the resolution of inflammation and tissue regeneration or per-
sistent injury and progression to tissue atrophy, whereby their 
heterogeneity is determined by the microenvironment (30–32). 
We, therefore, carried out flow cytometry analysis to understand 
the diversity of phenotypes among the infiltrating macrophages. 
FigUre 2 | IgG antibody treatment improves renal outcome in CaOx crystal-induced injury in vivo. (a) Mice were either fed an oxalate-rich diet for 14 days (oxalate 
only) or were additionally injected with an IgG1 (oxalate + IgG1) or anti-transforming growth factor (TGF)β IgG antibody (oxalate + anti-TGFβ) or fed a control diet 
(control) (total 7 i.p. injections). (a) Quantification of CaOx crystal deposition (% area) in cortex, outer and inner medulla of Pizzolato stained kidney sections from the 
four groups on day 14. (b) Renal functional parameter serum blood urea nitrogen (BUN) levels on day 14. (c) Periodic acid-Schiff (PAS) staining illustrating tubular 
injury (original magnification 20×) and quantification of the tubular injury score. (D) Intrarenal mRNA expression of the kidney injury marker (KIM)-1 and tissue inhibitor 
of metalloproteinase (TIMP)-2. Data are mean ± SEM from five mice per group out of two independent experiments. ns, not significant. *p < 0.05, **p < 0.01, 
***p < 0.001 are considered significant.
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We noted that nephrocalcinosis is associated with increased 
numbers of CD45+ leukocytes in IgG1-treated mice compared 
to the control group (Figures  4A,B). However, anti-TGFβ IgG 
treatment significantly reduced the number of CD45+ leuko-
cytes in mice with nephrocalcinosis (Figure  4B). The infiltrat-
ing macrophages were identified as CD45+ F4/80+ CD11b+ 
(Figure  4B). Phenotype analysis of macrophages revealed that 
these were pro-inflammatory (M1-like) macrophages (CD45+ 
F4/80+ CD11b+ CX3CR1+ CD206−) and M2-like macrophages 
(CD45+ F4/80+ CD11b+ CX3CR1+ CD206+) (Figure  4A) 
(30). Upon anti-TGFβ antibody treatment, the number of renal 
pro-inflammatory macrophages was significantly reduced com-
pared to IgG1-treated or untreated mice with nephrocalcinosis 
(Figure  4C), which was consistent with less intrarenal mRNA 
expression of inducible nitric oxide synthase (iNOS), a media-
tor of inflammatory responses (Figure 4D). This indicates that 
anti-TGFβ treatment reduces the number of pro-inflammatory 
(M1-like) macrophages during nephrocalcinosis.
The Dual effect of anti-TgFβ igg 
suppresses nephrocalcinosis-related 
interstitial Fibrosis
Progressive nephrocalcinosis is associated with diffuse interstitial 
fibrosis, a process widely thought to contribute to CKD wors-
ening (13, 33). We next investigated the impact of anti-TGFβ 
antibody treatment on interstitial fibrosis during chronic CaOx 
crystal-induced nephropathy. Immunohistochemistry staining 
FigUre 3 | Anti-transforming growth factor (TGF)β IgG treatment ameliorates renal inflammation in chronic oxalate nephropathy. C57BL/6N mice were either fed 
an oxalate-rich diet for 14 days (oxalate only) or were additionally injected with an IgG1 (oxalate + IgG1) or anti-TGFβ antibody (oxalate + anti-TGFβ) or fed a 
control diet (control) (total 7 i.p. injections). (a) Intrarenal mRNA expression of the inflammatory cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)α.  
(b) Immunostaining illustrating infiltrating CD3+ T cells and F4/80+ macrophages on kidney sections. (c,D) Intrarenal mRNA of the fatty acid enzymes 
peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC1α), peroxisome proliferator-activated receptor alpha (PPARα), and peroxisomal 
acyl-coenzyme A oxidase 1 (ACOX1) (c), and of the TGFβ signaling-related genes TGFβ1 and TGFβ2 as well as the receptors TGFβR1 and TGFβR2 (D) was 
performed on kidney RNA isolates. Data are mean ± SEM from five mice per group out of two independent experiments. ns, not significant. *p < 0.05, **p < 0.01, 
***p < 0.001 are considered significant.
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FigUre 4 | Treatment with the anti-transforming growth factor (TGF)β IgG antibody decreases nephrocalcinosis-related macrophage infiltrates. C57BL/6N mice were 
either fed a control diet, a high-oxalate diet only or combined with IgG1 or anti-TGFβ antibody treatment for 14 days. (a,b) Flow cytometric analysis of infiltrating 
CD45+ leukocytes and gating strategy of CD45+ F4/80+ CD11b+ macrophages in kidneys with absolute numbers. (c) Renal infiltrating macrophages identified as 
pro-inflammatory (M1-like) (CD45+ F4/80+ CD11b+ CX3CR1+ CD206−) macrophages with absolute cell numbers. (D) mRNA expression of inducible nitric oxide 
synthase (iNOS) was performed on kidney RNA isolates. (e,F) Absolute cell numbers of pro-fibrotic (M2a-like) macrophages (CD45+ F4/80+ CD11b+ CX3CR1+ 
CD206+ TGFβ+) (e) and anti-inflammatory (M2c-like) macrophages (CD45+ F4/80+ CD11b+ CX3CR1+ CD206+ TGFβ−) (F) in the kidneys. Data are mean ± SEM 
from six to seven mice per group out of two independent experiments. ns, not significant. *p < 0.05, **p < 0.01, ***p < 0.001 are considered significant.
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of kidney sections for silver and αSMA revealed an increase of 
fibrotic lesions in mice with nephrocalcinosis as demonstrated 
by % area (Figures 5A,B). Following anti-TGFβ or IgG1 antibody 
treatment, however, we observed significantly less fibrosis 
(Figures  5A,B), which was in line with decreased intrarenal 
mRNA expression levels of the fibrosis marker collagen-1α1 and 
FigUre 5 | Neutralizing transforming growth factor (TGF)β inhibits nephrocalcinosis-related fibrosis. C57BL/6N mice were fed a high-oxalate diet only or in 
combination with preemptive IgG1 or anti-TGFβ antibody treatment for 14 days. (a,b) Immunohistochemistry images (a) and quantification of silver and alpha 
smooth muscle actin (αSMA) staining (b) was performed on kidney sections. (c) mRNA expression of collagen1α1 and fibronectin-1 was performed on kidney RNA 
isolates. (D) Magnetic resonance imaging of kidneys of IgG1 or anti-TGFβ antibody-treated mice with nephrocalcinosis. Representative images and quantification of 
T1 and T2 relaxation interval time showed significant differences in inflammation and fibrosis between the two groups. Data are mean ± SEM from five mice in each 
group. ns, not significant. *p < 0.05, **p < 0.01, ***p < 0.001 are considered significant.
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fibronectin-1 in the anti-TGFβ antibody treatment compared 
to the oxalate only group (Figure 5C). Further flow cytometry 
analysis showed that the number of pro-fibrotic (M2a-like) mac-
rophages (CD45+ F4/80+ CD11b+ CX3CR1+ CD206+ TGFβ+) 
(34) significantly decreased (Figure 4E), whereas the number of 
anti-inflammatory (M2c-like) macrophages (CD45+ F4/80+ 
CD11b+ CX3CR1+ CD206+ TGFβ−) increased (Figure  4F) 
upon anti-TGFβ treatment in mice with nephrocalcinosis. In 
addition, we performed MRI of kidneys from mice with nephro-
calcinosis. Compared to mice given the IgG1 antibody, animals 
receiving the anti-TGFβ antibody displayed a significant decrease 
in T1 and T2 time interval in the MRI analysis, suggesting less 
11
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renal inflammation and fibrosis following TGFβ neutralization 
in mice with nephrocalcinosis (Figure 5D). Together, inhibiting 
fibrosis attenuates nephrocalcinosis-related CKD in association 
with a shift from pro-inflammatory (M1-like) and pro-fibrotic 
(M2a-like) macrophages toward an anti-inflammatory (M2c-
like) macrophage phenotype.
Preemptive but not Delayed-Onset 
inhibition of TgFβ-Mediated interstitial 
Fibrosis Prevents Progressive gFr Decline
To study the impact of less interstitial fibrosis on progressive GFR 
decline, we repetitively measured GFR in mice on oxalate diet (day 
0 and 14) or control diet (day 14). The GFR measurement process 
relies on a percutaneous acquisition of the clearance kinetics of a 
fluorescent signal emitted by the fluorescent tracer FITC-sinistrin 
upon bolus injection, a diagnostic tool in rodents (13, 35) and 
humans (36). We used a three-compartment kinetic model with 
linear correction to determine the GFR in mice. This model cov-
ers the injection process, the plasma volume, and the interstitial 
compartment allowing further refinement by correcting for shifts 
observed occasionally during measurements (37). After injecting 
FITC-sinistrin into a mouse that was fed a control diet (control) 
for 14 days, the fluorescent signal quickly increased at the begin-
ning and descends down to the initial baseline level as it gets 
filtered by the kidneys after approximately 90 min. An example is 
illustrated in Figure 6A. The fluorescent signal of FITC-sinistrin 
was automatically recorded and the half-life (t1/2) determined 
(curve fitting 40% after peak signal, green dotted line) for calcu-
lating the GFR (21). Feeding mice an oxalate-rich diet resulted in 
an impaired renal clearance of FITC-sinistrin as indicated by the 
higher fluorescence intensity after 90 min (Figure 6B) compared 
to the FITC-sinistrin signal from a healthy mouse (Figure 6A). 
However, preemptive anti-TGFβ IgG therapy resulted in a 
decrease in the fluorescence intensity of FITC-sinistrin of mice 
with nephrocalcinosis after 90 min (Figure 6D) compared to an 
IgG1-treated mouse with nephrocalcinosis (Figure 6C).
Next, we calculated the three effect sizes: (1) the slope of daily 
GFR decline, (2) the GFR at the end of the study, and (3) the 
end stage renal disease (ESRD)-free renal survival. As illustrated 
in Figure 6E, the daily GFR loss was calculated using the linear 
equation (solid lines) between baseline (day 0) and day 14 indi-
cating the slope (m) of the linear lines. Using this linear equation, 
we extended these lines (dotted lines) up to when they reached 
the GFR cut off of 15 μl/min/100  g BW, which we defined as 
ESRD (gray range). We found that the slope of daily GFR loss was 
m = −15.6 in mice with nephrocalcinosis (oxalate only, table and 
red line) compared to IgG1 treatment (m = −14.5) (Figure 6E, 
table and black line). However, preemptive TGFβ inhibition 
decreased the slope by Δ = 38.3% (m = −8.9) (Figure 6E, table 
and green line). At the end of the study on day 14, we observed a 
significant difference in the GFR in the IgG1-treated mice with an 
increase from 19.9 to 42.6 μl/min/100 g BW (Δ = 53.2%, p = 0.04) 
compared to oxalate-fed mice only (Figure 6E, table). This benefi-
cial effect on the GFR on day 14 was further improved by treating 
mice with the anti-TGFβ IgG antibody (42.6–120.4 μl/min/100 g 
BW) (Δ =  64.6%, p =  0.0007) compared to IgG1-treated mice 
with nephrocalcinosis (Figure 6E, table). Assuming a linear GFR 
decline in the future, IgG1 treatment extended the ESRD-free 
renal survival compared to untreated mice with nephrocalcinosis 
by 2 days (Δ = 12.5%, black dotted line). Anti-TGFβ IgG therapy 
on the other hand prolonged the ESRD-free renal survival time 
even up to 10 days (Δ = 38.5%, green dotted line) compared to 
IgG1-treated mice.
In a clinical setting, anti-fibrotic treatments might be mainly 
considered upon detecting renal fibrosis in a diagnostic kidney 
biopsy but the window-of-opportunity for targeting renal fibrosis 
in CKD is unknown. Therefore, we explored the capacity of a 
delayed anti-TGFβ IgG treatment to improve GFR in mice with 
nephrocalcinosis by initiating anti-TGFβ or control IgG1 therapy 
from day 7, a time point when some tubular atrophy had already 
established (Figure S2 in Supplementary Material). Assessing 
the renal excretory function, we observed no protective effect 
of TGFβ inhibition with any of the aforementioned parameters 
(Figure S2 in Supplementary Material). Together, the data show 
that preemptive inhibition of TGFβ-driven interstitial fibrosis 
significantly preserves GFR decline and increased the ESRD-free 
renal survival of mice with progressive nephrocalcinosis-related 
CKD. However, delayed onset of TGFβ inhibition does no longer 
attenuate renal function decline or expand the ESRD-free renal 
survival.
DiscUssiOn
We hypothesized that anti-TGFβ IgG antibody treatment may 
not only inhibit interstitial fibrosis but also influence the crystal-
lization of CaOx inside the kidney, which both should synergize 
to prevent nephrocalcinosis-related GFR decline. We now show 
that the anti-TGFβ IgG antibody has a dual role by influencing the 
crystallization process of CaOx crystals and inhibiting interstitial 
fibrosis in a mouse model of progressive CaOx crystal-induced 
nephropathy.
In kidney stone disease or nephrocalcinosis, interactions 
between urinary constituents and CaOx crystals may influence 
one or more critical processes in the stone pathogenesis, including 
crystal nucleation, aggregation, growth, and adhesion of crystals 
and/or aggregates to the epithelial cell surface in the kidney (38). 
The mechanism of CaOx crystallization involves a combination 
of processes, including urine supersaturation of stone-forming 
salts, such as calcium and oxalate, urinary pH (6, 7, 39). A variety 
of urinary constituents have been identified as possible inhibitors 
of CaOx crystallization, growth, and cell membrane adhesion, 
in particular macromolecules (40–42), proteins (9, 10, 43–45), 
and phospholipids (46). Unlike healthy individuals, patients 
with CaOx nephrolithiasis or nephrocalcinosis show decreased 
urinary CaOx crystallization inhibitors. CaOx crystals can be 
coated with alternating electron-dense and light fibrils, or covered 
with a more amorphous granular material indicating binding of 
proteins to CaOx crystals (8, 47). Using a proteomics approach, 
Fong-ngern et al. identified a large number of apical proteins on 
distal renal tubular epithelial cells that can bind to COM crystals 
(48). To our knowledge, we report for the first time that an anti-
TGFβ IgG and the control IgG1 antibody can influence CaOx 
FigUre 6 | Preemptive transforming growth factor (TGF)β neutralization attenuates progressive glomerular filtration rate (GFR) decline. C57BL/6N mice were either 
fed a control diet (control), a high-oxalate diet (oxalate only) or an oxalate-rich diet combined with preemptive IgG1 or anti-TGFβ antibody treatment (oxalate + IgG1 
and oxalate + anti-TGFβ) for up to 14 days. (a–D) Representative images of FITC-sinistrin fluorescence intensity curves using the three-compartment model with 
linear correction from a healthy mouse (control) (a), a mouse with nephrocalcinosis (b), an IgG1-treated mouse (c), or anti-TGFβ antibody-treated mouse (D) with 
nephrocalcinosis. (e) GFR decline of all four groups from day 0 to 14 illustrated by the effect sizes: linear equation with slope (m, colored lines), GFR on day 14, and 
time to end stage renal disease (ESRD) (dotted lines and table). Δ represents difference expressed in percent (%). Data are mean ± SEM from five to seven mice per 
group and representative of one out of two independent experiments.
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crystal formation in vitro as well as in vivo using a mouse model 
of progressive CaOx crystal-induced nephropathy. We also found 
that the IgG F(ab′)2 fragment can influence CaOx crystallization 
in  vitro. On the other hand, blocking TNFR signaling with 
Etanercept, a fusion protein consisting of an extracellular TNR 
receptor 2 and an Fc domain of the human IgG1, has been shown 
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to reduce renal CaOx crystal deposition and prevent progressive 
nephrocalcinosis in mice (49). Thus, the exact mechanism of 
CaOx crystallization counteracting with IgG1 or the two main 
fragments is currently unknown and will need further investiga-
tion. So far, therapeutic approaches in humans primarily focus on 
reducing the risk of recurrent CaOx crystal formation (50) via, 
e.g., dietary restriction of oxalate-rich products (51), or reducing 
calcium and increasing citrate (52, 53).
Injury to every segment of the nephron can ultimately lead to 
loss of the entire nephron (54, 55). Toxic, inflammatory, or ischemic 
injury damages tubular cells leading to cell death, microvascular 
rarefaction, and fibroblast activation (56). Excessive myofibroblast 
accumulation of extracellular matrix in the interstitial and vascu-
lar compartment are accompanied by a significant decline in GFR 
and impaired epithelial regeneration (56). A variety of preclinical 
strategies to inhibit or even reverse interstitial fibrosis have been 
shown to be effective in rodents. For example, Kramann et  al. 
demonstrated in two kidney fibrosis models that inhibiting the 
hedgehog pathway transcriptional effector GLI2 reduced renal 
fibrosis by limiting myofibroblast proliferation (57). Our finding 
confirms that administration of an anti-TGFβ IgG antibody can 
effectively prevent interstitial fibrosis in progressive CKD (16, 
19, 58, 59). However, we did not observe a preservation of renal 
function upon delayed anti-TGFβ IgG antibody treatment. In 
addition, overexpression of latent TGFβ1 was shown to decrease 
both SMAD2/3 activation (transcription factors of canonical 
TGFβ1 signaling) and the number of myofibroblasts (60), which 
is in line with findings that SMAD3 knockout mice are protected 
from renal fibrosis (61, 62). Recent data also highlight a role for 
non-canonical TGFβ1 signaling via the transcription factor p53, 
a regulator of pro-fibrotic gene expression and cell cycle control in 
tubular epithelial cells (63–65), and for the complement factor C5 
as therapeutic targets for fibrosis-related CKD (66). Strategies and 
efficacy of pharmacological therapies to reduce CKD progression 
are of upmost need (67). A dual-specific antibody approach for 
TGFβ neutralization successfully attenuated fibrosis in a mouse 
model of UUO (68). On the other hand, blocking TGFβ and 
Wnt-activated β-catenin crosstalk in proximal tubules enhances 
progressive CKD (69), suggesting that TβRII activity and the lack 
of proximal tubules stability may exacerbate fibrosis (70). Other 
than determining serum BUN and creatinine levels as well as 
other excretory markers of renal function, these animal studies 
did not assess GFR as primary endpoint. In our preclinical study, 
we used the transcutaneous GFR system based on the fluorescent 
tracer FITC-sinistrin, which is a precise method for repeated 
measurements in conscious and unrestricted mice to calculate 
the GFR (21, 22, 35, 37). Fresolimumab, a TGFβ neutralizing anti-
body did not elicit any positive effect on the GFR in a randomized 
control trial including 416 patients with diabetic kidney disease 
(71). Moreover, the anti-fibrotic agent pirfenidone was reported 
to consistently attenuate the GFR decline in mice and humans 
(72, 73).
In summary, anti-TGFβ IgG antibody treatment inhibits both 
CaOx crystallization and interstitial fibrosis in a model of CaOx 
crystal-induced nephropathy. Blocking TGFβ significantly 
improved the GFR decline by 38.3%, increased the GFR at the end 
of the study by 64.6%, and prolonged the time to ESRD by 38.5% 
compared to IgG1 control treatment. However, this nephropro-
tective effect got lost upon delayed onset of TGFβ blockade. We 
conclude that anti-TGFβ IgG antibody treatment elicits a dual 
effect on CaOx crystallization and interstitial fibrosis, which 
represents a novel therapeutic approach to delay progressive 
nephrocalcinosis-related CKD.
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FigUre s1 | Anti-TGFβ IgG treatment decreases oxaluria but has no effect on 
calcinuria. C57BL/6N mice were either fed a control diet (control), a high-oxalate 
diet (oxalate only) or an oxalate-rich diet combined with preemptive IgG1 or 
anti-TGFβ antibody treatment (oxalate + IgG1 and oxalate + anti-TGFβ) for up to 
14 days. Serum and urine oxalate levels (a) and urine calcium levels (b) on day 
14. Data are mean ± SEM from five mice per group. ns, not significant. 
*p < 0.05, **p < 0.01, ***p < 0.001 are considered significant.
FigUre s2 | Delayed anti-TGFβ IgG treatment does not improve renal function 
in chronic oxalate nephropathy. (a) Flow diagram of experimental design: 
C57BL/6N mice were fed an oxalate-rich diet combined with delayed IgG1 or 
anti-TGFβ treatment (total of 4 i.p. injections) (oxalate + IgG1 or oxalate + anti-
TGFβ) compared to control diet (control) for 14 days. (b–D) Renal function was 
assessed by determining the serum blood urea nitrogen (BUN) levels (b), tubular 
injury by periodic acid-Schiff (PAS) staining (c), and measuring the glomerular 
filtration rate (GFR) (D) on day 14. Data are mean ± SEM from five mice per 
group. ns, not significant. *p < 0.05, **p < 0.01, ***p < 0.001 are considered 
significant.
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